{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:25:34Z","timestamp":1791588334834,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,4,2]],"date-time":"2010-04-02T00:00:00Z","timestamp":1270166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1007\/s10549-010-0866-3","type":"journal-article","created":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T09:33:29Z","timestamp":1270114409000},"page":"181-188","source":"Crossref","is-referenced-by-count":226,"title":["Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer"],"prefix":"10.1007","volume":"122","author":[{"given":"Valentina","family":"Guarneri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Di\u00e9ras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thomssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PierFranco","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,2]]},"reference":[{"key":"866_CR1","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666\u20132676","journal-title":"N Engl J Med"},{"key":"866_CR2","doi-asserted-by":"crossref","unstructured":"Miles D, Chan A, Romieu G Dirix LY, Cortes J, Pivot X, Tomczak P, Taran T, Harbeck N, Steger GG (2008) Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26(Suppl): (Abstract LBA1011)","DOI":"10.1200\/jco.2008.26.15_suppl.lba1011"},{"key":"866_CR3","doi-asserted-by":"crossref","unstructured":"Robert NJ, Dieras V, Glaspy J et al. (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 27(15s): (Abstract 1005)","DOI":"10.1016\/S1359-6349(09)70908-5"},{"key":"866_CR4","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180\u20135186","journal-title":"J Clin Oncol"},{"key":"866_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10:559\u2013568","journal-title":"Lancet Oncol"},{"key":"866_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-008-0549-x","volume":"38","author":"IR Reid","year":"2009","unstructured":"Reid IR, Cundy T (2009) Osteonecrosis of the jaw. Skelet Radiol 38:5\u20139","journal-title":"Skelet Radiol"},{"key":"866_CR7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826\u2013836","journal-title":"J Bone Miner Res"},{"key":"866_CR8","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"866_CR9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","volume":"27","author":"JB Aragon-Ching","year":"2009","unstructured":"Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27:221\u2013226","journal-title":"Cancer Invest"},{"key":"866_CR10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","volume":"17","author":"G Sanna","year":"2006","unstructured":"Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nol\u00e8 F (2006) Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 17:1512\u20131516","journal-title":"Ann Oncol"},{"key":"866_CR11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99\u2013102","journal-title":"N Engl J Med"},{"key":"866_CR12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","volume":"115","author":"C Walter","year":"2009","unstructured":"Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Gr\u00f6tz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631\u20131637","journal-title":"Cancer"},{"key":"866_CR13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1634\/theoncologist.10-10-842","volume":"10","author":"V Guarneri","year":"2005","unstructured":"Guarneri V, Donati S, Nicolini M, Giovannelli S, D\u2019Amico R, Conte PF (2005) Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 10:842\u2013848","journal-title":"Oncologist"},{"key":"866_CR14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","volume":"65","author":"EP Wang","year":"2007","unstructured":"Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ (2007) Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65:1328\u20131331","journal-title":"J Oral Maxillofac Surg"},{"key":"866_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","volume":"112","author":"T Fehm","year":"2009","unstructured":"Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynaecological malignancies. Gynecol Oncol 112:605\u2013609","journal-title":"Gynecol Oncol"},{"issue":"5 Suppl","key":"866_CR16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"67","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61\u201370","journal-title":"J Oral Maxillofac Surg"},{"key":"866_CR17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/annonc\/mdg194","volume":"14","author":"B Vincenzi","year":"2003","unstructured":"Vincenzi B, Santini D, Rocci L, Tonini G (2003) Bisphosphonates: new antiangiogenic molecules in cancer treatment? Ann Oncol 14:806","journal-title":"Ann Oncol"},{"issue":"15 Pt 1","key":"866_CR18","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","volume":"13","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G (2007) Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13(15 Pt 1):4482\u20134486","journal-title":"Clin Cancer Res"},{"key":"866_CR19","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","volume":"26","author":"CL Estilo","year":"2008","unstructured":"Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM (2008) Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26:4037\u20134038","journal-title":"J Clin Oncol"},{"key":"866_CR20","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","volume":"19","author":"S Greuter","year":"2008","unstructured":"Greuter S, Schmid F, Ruhstaller T, Thuerlimann B (2008) Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 19:2091\u20132092","journal-title":"Ann Oncol"},{"key":"866_CR21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G, Batziou E, Skarlos DV (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209\u2013211","journal-title":"Oncology"},{"key":"866_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","volume":"44","author":"A Brunello","year":"2009","unstructured":"Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173\u2013175","journal-title":"Bone"},{"key":"866_CR23","doi-asserted-by":"crossref","unstructured":"Bonomi L, Bettini A, Bonacina R, Villa F, Mariani U, Rota Caremoli E, Tondini C (2009) Efficacy of a surveillance dental programme on prevention of osteonecrosis of the jaw in cancer patients with bone metastases: a single institution preliminary experience. Eur J Cancer Suppl 7:199 (Abstract 3082)","DOI":"10.1016\/S1359-6349(09)70681-0"},{"key":"866_CR24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2353\/ajpath.2006.050874","volume":"168","author":"ML Cher","year":"2006","unstructured":"Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LW (2006) Cancer interaction with the bone microenvironment. Am J Pathol 168:1405\u20131412","journal-title":"Am J Pathol"},{"key":"866_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-5793(00)01520-9","volume":"473","author":"M Nakagawa","year":"2000","unstructured":"Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y (2000) Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 473:161\u2013164","journal-title":"FEBS Lett"},{"key":"866_CR26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","volume":"335","author":"SE Aldridge","year":"2005","unstructured":"Aldridge SE, Lennard TW, Williams JR, Birch MA (2005) Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun 335:793\u2013798","journal-title":"Biochem Biophys Res Commun"},{"key":"866_CR27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","volume":"63","author":"RE Marx","year":"2005","unstructured":"Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567\u20131575","journal-title":"J Oral Maxillofac Surg"},{"key":"866_CR28","doi-asserted-by":"crossref","unstructured":"Cortes-Funes H, Pritchard KI, Biganzoli L, Thomssen C, Pierga J, Koza I, Kwong A, Kellokunpu-Lehitinen P, Chlistalla A, Smith I (2009) Multinational study (n\u00a0=\u00a02041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR\/mBC): updated results of MO19391. Eur J Cancer Suppl 7(2):265 (Abstract 5017)","DOI":"10.1016\/S1359-6349(09)70909-7"},{"key":"866_CR29","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1200\/jco.2008.26.15_suppl.9588","volume":"26","author":"HL McArthur","year":"2008","unstructured":"McArthur HL, Estilo C, Huryn J, Williams T, Fornier M, Traina TA, Howard J, Hudis CA, Dickler MN (2008) Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and\/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 26:9588","journal-title":"J Clin Oncol"},{"key":"866_CR30","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753\u2013761","journal-title":"Ann Intern Med"},{"key":"866_CR31","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","volume":"26","author":"A Kyrgidis","year":"2008","unstructured":"Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, Patrikidou A, Triaridis S (2008) Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634\u20134638","journal-title":"J Clin Oncol"},{"key":"866_CR32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","volume":"116","author":"D Mauri","year":"2009","unstructured":"Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116:433\u2013439","journal-title":"Breast Cancer Res Treat"},{"key":"866_CR33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","volume":"28","author":"AE King","year":"2008","unstructured":"King AE, Umland EM (2008) Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 28:667\u2013677","journal-title":"Pharmacotherapy"},{"key":"866_CR34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","volume":"46","author":"C Ortega","year":"2007","unstructured":"Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, Gilardino MO, Aglietta M (2007) Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 46:664\u2013668","journal-title":"Acta Oncol"},{"key":"866_CR35","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","volume":"27","author":"K Vahtsevanos","year":"2009","unstructured":"Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356\u20135362","journal-title":"J Clin Oncol"},{"key":"866_CR36","first-page":"1391","volume":"35","author":"AA Khan","year":"2008","unstructured":"Khan AA, S\u00e1ndor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE, Canadian Association of Oral, Maxillofacial Surgeons (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391\u20131397","journal-title":"J Rheumatol"},{"key":"866_CR37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1445-5994.2008.01824.x","volume":"39","author":"M Dickinson","year":"2009","unstructured":"Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin L, O\u2019Grady J, Seymour JF, Szer J, Horvath N, Joshua DE (2009) Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 39:304\u2013316","journal-title":"Intern Med J"},{"key":"866_CR38","first-page":"3369","volume":"61","author":"CJ Sweeney","year":"2001","unstructured":"Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369\u20133372","journal-title":"Cancer Res"},{"key":"866_CR39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145","journal-title":"Ann Oncol"},{"issue":"18S","key":"866_CR40","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1200\/jco.2007.25.18_suppl.6519","volume":"25","author":"BJ Edwards","year":"2007","unstructured":"Edwards BJ, Gounder M, McKoy J, Raisch D, Farrugia M, Cesar M, Marx R, Ruggiero S, Dimopoulos M, Bennett C (2007) Bisphosphonate use and osteonecrosis of the jaw: pharmacovigilance and reporting of this serious adverse event from the Research on Adverse Drug Events and Reports (RADAR) project. J Clin Oncol 25(18S):6519","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-0866-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-0866-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T12:41:45Z","timestamp":1591188105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-0866-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-0866-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,2]]}}}